Sponsors (9)
This bill channels federal and NIH attention to improve research, diagnosis, and treatments for people with Down syndrome—potentially improving health and inclusion—but it increases federal spending, may divert resources from other research areas, and raises ethical and rights-framing risks that require strong safeguards.
People with Down syndrome (and their families) will receive more targeted medical research, training, and care leading to improved diagnosis, treatment, quality of life, and potentially longer lifespans.
Patients with Down syndrome could gain greater access to clinical trials, including novel biomedical and pharmacological interventions that might offer new treatment options.
NIH coordination and technical assistance for Down syndrome research should reduce duplication, improve efficiency, and strengthen the quality of studies.
Directing new research and programmatic efforts toward Down syndrome will increase federal spending and administration costs, which could raise taxpayer burdens or require tradeoffs elsewhere in the budget.
Prioritizing Down syndrome research and resources could reallocate limited NIH funds away from other conditions, potentially slowing research or care advances for other patient groups.
Expanding clinical trials in a vulnerable population raises ethical and safety risks if the bill does not ensure strong oversight, informed consent safeguards, and protections against exploitation.
Based on analysis of 3 sections of legislative text.
Creates an NIH-led program to coordinate and fund Down syndrome research, build a large study cohort, expand inclusive clinical trials, and report biennially to Congress.
Establishes an NIH-led program to coordinate and fund research, training, and clinical investigation focused on Down syndrome. The program will support basic and clinical science, build a large national Down syndrome study population, expand inclusive clinical trials, study co-occurring conditions and biomarkers, and require biennial reports to Congress describing supported research and real-world evidence. The program is carried out by the Office of the Director of NIH (directly or through grants and contracts) with interagency and partner consultation, technical assistance for grantees, and steps to avoid duplication across NIH components.
Introduced May 21, 2025 by John Wright Hickenlooper · Last progress May 21, 2025